Efficacy of Vesicular Stomatitis Virus-Ebola Virus Postexposure Treatment in Rhesus Macaques Infected with Ebola Virus Makona

Journal of Infectious Diseases

Volumn 214, Issue , 2016, Pages S360-S366

  Marzi, Andrea ^a   Hanley, Patrick W ^b   Haddock, Elaine ^a   Martellaro, Cynthia ^a   Kobinger, Gary ^c   Feldmann, Heinz ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c PUBLIC HEALTH AGENCY OF CANADA   (Canada)

Author keywords

Ebola virus; Postexposure treatment; Rhesus macaque; VSV EBOV

Indexed keywords

ALPHA INTERFERON; GAMMA INTERFERON; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; INTERLEUKIN 15; UNCLASSIFIED DRUG; VESICULAR STOMATITIS VIRUS EBOLA VIRUS VACCINE; VIRUS VACCINE; EBOLA VACCINE; VIRUS ANTIBODY;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG DOSE COMPARISON; DRUG DOSE REGIMEN; DRUG EFFICACY; EBOLA HEMORRHAGIC FEVER; EBOLAVIRUS; EBOLAVIRUS MAKONA; FEMALE; HUMORAL IMMUNITY; INFECTION PREVENTION; INNATE IMMUNITY; MACROPHAGE ACTIVATION; MALE; NONHUMAN; POST EXPOSURE PROPHYLAXIS; PRIORITY JOURNAL; RHESUS MONKEY; SURVIVAL RATE; SURVIVAL TIME; TIME SERIES ANALYSIS; VIREMIA; VIRUS LOAD; VIRUS REPLICATION; VIRUS TITRATION; AFRICA; ANIMAL; EPIDEMIOLOGY; HEMORRHAGIC FEVER, EBOLA; HUMAN; IMMUNOLOGY; MARBURGVIRUS; VACCINATION; VESICULAR STOMATITIS; VESICULOVIRUS; VIROLOGY;

AFRICA, WESTERN; ANIMALS; ANTIBODIES, VIRAL; EBOLA VACCINES; EBOLAVIRUS; FEMALE; HEMORRHAGIC FEVER, EBOLA; HUMANS; MACACA MULATTA; MALE; MARBURGVIRUS; VACCINATION; VESICULAR STOMATITIS; VESICULOVIRUS;

EID: 84990936358     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jiw218     Document Type: Article

References (33)

1. Feldmann H, Geisbert TW. Ebola haemorrhagic fever. Lancet 2011; 377:849-62.
2. World Health Organization. Ebola situation report, 30 March 2016. Geneva, Switzerland: World Health Organization, 2016.
3. Marzi A, Feldmann H. Ebola virus vaccines: an overview of current approaches. Expert Rev Vaccines 2014; 13:521-31.
4. Wong G, Qiu X, Olinger GG, Kobinger GP. Post-exposure therapy of filovirus infections. Trends Microbiol 2014; 22:456-63.
5. Jones SM, Feldmann H, Stroher U, et al. Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses. Nat Med 2005; 11:786-90.
6. Marzi A, Robertson SJ, Haddock E, et al. Ebola vaccine: VSV-EBOV rapidly protects macaques against infection with the 2014/15 Ebola virus outbreak strain. Science 2015; 349:739-42.
7. Agnandji ST, Huttner A, Zinser ME, et al. Phase 1 trials of rVSV Ebola vaccine in Africa and Europe-preliminary report. N Engl J Med 2016; 374:1647-60.
8. Regules JA, Beigel JH, Paolino KM, et al. A recombinant vesicular stomatitis virus Ebola vaccine-preliminary report. N Engl J Med 2015; doi:10.1056/NEJMoa1414216.
9. Huttner A, Dayer JA, Yerly S, et al. The effect of dose on the safety and immunogenicity of the VSV Ebola candidate vaccine: a randomised double-blind, placebocontrolled phase 1/2 trial. Lancet Infect Dis 2015; 15:1156-66.
10. Henao-Restrepo AM, Longini IM, Egger M, et al. Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein: interim results from the Guinea ring vaccination cluster-randomised trial. Lancet 2015; 386:857-66.
11. Feldmann H, Jones SM, Daddario-DiCaprio KM, et al. Effective post-exposure treatment of Ebola infection. PLoS Pathog 2007; 3:e2.
12. Gunther S, Feldmann H, Geisbert TW, et al. Management of accidental exposure to Ebola virus in the biosafety level 4 laboratory, Hamburg, Germany. J Infect Dis 2011; 204(suppl 3):S785-90.
13. Baize S, Pannetier D, Oestereich L, et al. Emergence of Zaire Ebola virus disease in Guinea. N Engl J Med 2014; 371:1418-25.
14. Marzi A, Feldmann F, Hanley PW, Scott DP, Gunther S, Feldmann H. Delayed disease progression in cynomolgus macaques infected with Ebola virus Makona strain. Emerg Infect Dis 2015; 21:1777-83.
15. Geisbert TW, Strong JE, Feldmann H. Considerations in the use of nonhuman primate models of Ebola virus and Marburg virus infection. J Infect Dis 2015; 212(suppl 2):S91-7.
16. Reed LJ, Muench H. A simple method of estimating fifty percent endpoints. Am J Hyg 1938; 27:493-7.
17. Nakayama E, Yokoyama A, Miyamoto H, et al. Enzyme-linked immunosorbent assay for detection of filovirus species-specific antibodies. Clin Vaccine Immunol 2010; 17:1723-8.
18. Mire CE, Matassov D, Geisbert JB, et al. Single-dose attenuated Vesiculovax vaccines protect primates against Ebola Makona virus. Nature 2015; 520: 688-91.
19. Lai L, Davey R, Beck A, et al. Emergency postexposure vaccination with vesicular stomatitis virus-vectored Ebola vaccine after needlestick. JAMA 2015; 313: 1249-55.
20. Marzi A, Kercher L, Marceau J, et al. Stat1-deficient mice are not an appropriate model for efficacy testing of recombinant vesicular stomatitis virus-based filovirus vaccines. J Infect Dis 2015; 212(suppl 2):S404-9.
21. Marzi A, Engelmann F, Feldmann F, et al. Antibodies are necessary for rVSV/ZEBOV-GP-mediated protection against lethal Ebola virus challenge in nonhuman primates. Proc Natl Acad Sci USA 2013; 110:1893-8.
22. Roberts A, Kretzschmar E, Perkins AS, et al. Vaccination with a recombinant vesicular stomatitis virus expressing an influenza virus hemagglutinin provides complete protection from influenza virus challenge. J Virol 1998; 72:4704-11.
23. Roberts A, Buonocore L, Price R, Forman J, Rose JK. Attenuated vesicular stomatitis viruses as vaccine vectors. J Virol 1999; 73:3723-32.
24. Basler CF,Wang X, Muhlberger E, et al. The Ebola virus VP35 protein functions as a type I IFN antagonist. Proc Natl Acad Sci USA 2000; 97:12289-94.
25. Mateo M, Reid SP, Leung LW, Basler CF, Volchkov VE. Ebolavirus VP24 binding to karyopherins is required for inhibition of interferon signaling. J Virol 2010; 84:1169-75.
26. Geisbert TW, Hensley LE, Larsen T, et al. Pathogenesis of Ebola hemorrhagic fever in cynomolgus macaques: evidence that dendritic cells are early and sustained targets of infection. Am J Pathol 2003; 163:2347-70.
27. Schoenborn JR, Wilson CB. Regulation of interferon-gamma during innate and adaptive immune responses. Adv Immunol 2007; 96:41-101.
28. EbiharaH, Rockx B,MarziA, et al.Host response dynamics following lethal infection of rhesus macaques with Zaire ebolavirus. J Infect Dis 2011; 204(suppl 3):S991-9.
29. Martins K, Cooper C, Warren T, et al. Characterization of clinical and immunological parameters during Ebola virus infection of rhesus macaques. Viral Immunol 2015; 28:32-41.
30. Mendoza EJ, Qiu X, Kobinger GP. Progression of Ebola therapeutics during the 2014-2015 outbreak. Trends Mol Med 2016; 22:164-73.
31. Qiu X, Wong G, Audet J, et al. Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp. Nature 2014; 514:47-53.
32. Thi EP, Mire CE, Lee AC, et al. Lipid nanoparticle siRNA treatment of Ebolavirus-Makona-infected nonhuman primates. Nature 2015; 521:362-5.
33. Warren TK, Jordan R, Lo MK, et al. Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys. Nature 2016; 531:381-5.